Authorized purpose: Provides quantitative coronary-plaque analysis using Agatston scoring, RCA/LCA segmentation, and calcium-score, gender, and age percentile risk stratification.
Clinical role
Quantitative analysis of calcified coronary plaque on non-contrast/non-gated chest CT: calculates the Agatston score while segmenting and evaluating the right and left coronary arteries, and provides percentile-based risk stratification by calcium score, gender, and age.
Images and patients
CT/CTA · Heart and coronary arteries
Key limitation
Keep in mind: Other CT manufacturers were not validated or recommended.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provides quantitative coronary-plaque analysis using Agatston scoring, RCA/LCA segmentation, and calcium-score, gender, and age percentile risk stratification.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart and coronary arteries Input: Existing DICOM 3.0 non-contrast, non-gated chest CT from specified GE or GE-subsidiary acquisitions in adults over 40 years.
Who uses it?Intended users: Healthcare professionals, including radiologists and cardiologists.
What does the software produce?Output: Agatston score, RCA/LCA evaluation, and percentile risk categories.
What is its most important limitation?Key limitation: Other CT manufacturers were not validated or recommended.
Clinical takeaway. Clinical role: Provides quantitative coronary-plaque analysis using Agatston scoring, RCA/LCA segmentation, and calcium-score, gender, and age percentile risk stratification.
Evidence takeaway. Evidence from the reviewed source record: No clinical study was necessary; nonclinical testing used 150 gated and 150 non-gated cases, with ICC versus ground truth of 0.896 total, 0.927 LCA, and 0.840 RCA.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Provides quantitative coronary-plaque analysis using Agatston scoring, RCA/LCA segmentation, and calcium-score, gender, and age percentile risk stratification.
Exact FDA submission
Checked 2026-09-15
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Quantitative analysis of calcified coronary plaque on non-contrast/non-gated chest CT: calculates the Agatston score while segmenting and evaluating the right and left coronary arteries, and provides percentile-based risk stratification by calcium score, gender, and age.
Exact FDA submission
Checked 2026-11-14
Packet wording: "AVIEW CAC provides quantitative analysis of calcified plaques in the coronary arteries using non-contrast/non-gated Chest CT scans." … "It enables the calculation of the Agatston score for coronary artery calcification, segmenting and evaluating the right coronary artery and left coronary artery.". Read from the exact FDA decision document on 2026-11-14.
No clinical study was necessary; nonclinical testing used 150 gated and 150 non-gated cases, with ICC versus ground truth of 0.896 total, 0.927 LCA, and 0.840 RCA.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
No clinical study was necessary; nonclinical testing used 150 gated and 150 non-gated cases, with ICC versus ground truth of 0.896 total, 0.927 LCA, and 0.840 RCA.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
AVIEW CAC regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K233211
Samplen=300
IndependenceIndependence not established
K233211
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233211. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Existing DICOM 3.0 non-contrast, non-gated chest CT from specified GE or GE-subsidiary acquisitions in adults over 40 years.
Scope: Exact FDA submission. Exact FDA input and compatibility scope.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes AVIEW CAC showing images from various storage devices using DICOM 3.0, receiving DICOM data from CT, conducting DICOM communication with PACS, importing DICOM files directly, and saving by using an export function. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "It shows images taken with the interface from various storage devices using DICOM 3.0, the digital image and communication standard in medicine." … "This receives DICOM data from CT by DICOM communication Conducts". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: On-premises deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Deployment mode explicitly reported in the exact-submission ACR model card; hosting region and current commercial configuration still require vendor confirmation.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Agatston score, RCA/LCA evaluation, and percentile risk categories.
Scope: Exact FDA submission. FDA output description.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
On-premises deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-09-01
Deployment mode explicitly reported in the exact-submission ACR model card; hosting region and current commercial configuration still require vendor confirmation.
The exact FDA package describes AVIEW CAC showing images from various storage devices using DICOM 3.0, receiving DICOM data from CT, conducting DICOM communication with PACS, importing DICOM files directly, and saving by using an export function. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "It shows images taken with the interface from various storage devices using DICOM 3.0, the digital image and communication standard in medicine." … "This receives DICOM data from CT by DICOM communication Conducts". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
On-premises deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K233211 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Provides non-invasive post-processing to quantify possible coronary calcifications and output Agatston score, arterial age, mass, and volume.
Authorized purpose: Non-invasive post-processing of routine non-gated, non-contrast CT studies containing the entire heart in adults aged 30 to 85 to evaluate coronary calcified plaque and estimate coronary calcium score and category.
Authorized purpose: Four-category coronary artery calcification (CAC) assessment of plaques on non-cardiac-gated, non-contrast CT images that include the heart; preview images are informational and the result is not for stand-alone clinical decision-making.
Authorized purpose: syngo.CT CaScoring analyzes noncontrast standard- or low-dose cardiac CT, marks calcified coronary lesions, allocates them to the right coronary, left main, left anterior descending, or circumflex artery, and calculates artery and total Agatston-equivalent, mass, and volume scores.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.